These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36044544)

  • 1. 2-(Fluoromethoxy)-4'-(
    García-Cárceles J; Vázquez-Villa H; Brea J; Ladron de Guevara-Miranda D; Cincilla G; Sánchez-Martínez M; Sánchez-Merino A; Algar S; Teresa de Los Frailes M; Roberts RS; Ballesteros JA; Rodríguez de Fonseca F; Benhamú B; Loza MI; López-Rodríguez ML
    J Med Chem; 2022 Sep; 65(18):12256-12272. PubMed ID: 36044544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
    Jenner P
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous dopaminergic tone and dopamine agonist action.
    Treseder SA; Smith LA; Jenner P
    Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics.
    Felsing DE; Jain MK; Allen JA
    Curr Top Med Chem; 2019; 19(16):1365-1380. PubMed ID: 31553283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    Gulwadi AG; Korpinen CD; Mailman RB; Nichols DE; Sit SY; Taber MT
    J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
    Farré D; Muñoz A; Moreno E; Reyes-Resina I; Canet-Pons J; Dopeso-Reyes IG; Rico AJ; Lluís C; Mallol J; Navarro G; Canela EI; Cortés A; Labandeira-García JL; Casadó V; Lanciego JL; Franco R
    Mol Neurobiol; 2015 Dec; 52(3):1408-1420. PubMed ID: 25344317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
    Sagot B; Li L; Zhou FM
    Front Neural Circuits; 2018; 12():57. PubMed ID: 30104963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
    Bruns RF; Mitchell SN; Wafford KA; Harper AJ; Shanks EA; Carter G; O'Neill MJ; Murray TK; Eastwood BJ; Schaus JM; Beck JP; Hao J; Witkin JM; Li X; Chernet E; Katner JS; Wang H; Ryder JW; Masquelin ME; Thompson LK; Love PL; Maren DL; Falcone JF; Menezes MM; Zhang L; Yang CR; Svensson KA
    Neuropharmacology; 2018 Jan; 128():351-365. PubMed ID: 29102759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral effects of cocaine: interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys.
    Katz JL; Kopajtic TA; Myers KA; Mitkus RJ; Chider M
    J Pharmacol Exp Ther; 1999 Oct; 291(1):265-79. PubMed ID: 10490913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R; Bédard PJ; Britton DR; Shiosaki K
    Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
    Brooks S; Kaur S; Starr BS; Starr MS
    J Neural Transm (Vienna); 1996; 103(6):737-48. PubMed ID: 8836935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
    Zengin-Toktas Y; Authier N; Denizot H; Chassain C; Hafidi A; Llorca PM; Durif F
    Neuropharmacology; 2013 Jul; 70():74-82. PubMed ID: 23347953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.